Post-traumatic stress disorder (PTSD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 Indication name: Post-traumatic stress disorder (PTSD)

Post-traumatic stress disorder (PTSD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Post-traumatic stress disorder (PTSD) is a complex mental disorder with psychological and emotional components, caused by exposure to single or repeated extreme traumatic events found in war, terrorist attacks, natural or man-caused disasters, and by violent personal assaults and accidents.

Epidemiology-

According to Thelansis, The lifetime prevalence of PTSD ranges from 5.7 to 8.8 percent in national samples of the general adult population in the United States, with one-year prevalence rates of 4.2 to 5.1 percent.

Competitive landscape of Post-traumatic stress disorder (PTSD) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Post-traumatic stress disorder (PTSD) 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Post-traumatic stress disorder (PTSD) market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Post-traumatic stress disorder (PTSD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 NYX-783 Aptinyx Phase 2
2 Nabiximols GW Pharmaceuticals Ltd. Phase 3
3 NBTX-001 Xenon Inhaler Nobilis Therapeutics Inc. Phase 3
4 BNC210 Bionomics Limited Phase 2
5 Brexpiprazole (OPC-34712) Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 3
6 CBD Cannabis Tilray Phase 2
7 orvepitant GlaxoSmithKline Phase 2
8 BX-1 Bionorica SE Phase 2
9 Ganaxolone Marinus Pharmaceuticals Phase 2
10 Lu AG06466 H. Lundbeck A/S Phase 1
11 MDMA MAPS Europe B.V. Phase 2
12 Nepicastat Acorda Therapeutics Phase 2
13 TNX-102 SL 5.6 mg Tonix Pharmaceuticals, Inc. Phase 3